Check-Cap Ltd. (CHEK)
USD 0.65
(-0.78%)
USD 0.65
(-0.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -17.56 Million USD | 8.76% |
| 2022 | -19.25 Million USD | -12.65% |
| 2021 | -17.09 Million USD | -24.21% |
| 2020 | -13.76 Million USD | -1.21% |
| 2019 | -13.59 Million USD | -28.4% |
| 2018 | -10.58 Million USD | -8.37% |
| 2017 | -9.77 Million USD | -10.71% |
| 2016 | -8.82 Million USD | 28.19% |
| 2015 | -12.29 Million USD | -201.52% |
| 2014 | -4.07 Million USD | -2.03% |
| 2013 | -3.99 Million USD | -7.36% |
| 2012 | -3.72 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -3.65 Million USD | -41.24% |
| 2023 Q2 | -6.87 Million USD | -70.5% |
| 2023 FY | -17.56 Million USD | 8.76% |
| 2023 Q1 | -4.03 Million USD | 2.77% |
| 2023 Q3 | -2.59 Million USD | 62.34% |
| 2022 FY | -19.25 Million USD | -12.65% |
| 2022 Q3 | -4.46 Million USD | 5.56% |
| 2022 Q4 | -4.14 Million USD | 7.04% |
| 2022 Q2 | -4.72 Million USD | 18.28% |
| 2022 Q1 | -5.78 Million USD | -5.59% |
| 2021 Q3 | -4.24 Million USD | -8.24% |
| 2021 Q2 | -3.91 Million USD | -9.87% |
| 2021 FY | -17.09 Million USD | -24.21% |
| 2021 Q4 | -5.47 Million USD | -29.14% |
| 2021 Q1 | -3.56 Million USD | 8.77% |
| 2020 Q4 | -3.9 Million USD | -8.04% |
| 2020 Q1 | -3.43 Million USD | 10.37% |
| 2020 Q2 | -2.88 Million USD | 15.83% |
| 2020 Q3 | -3.61 Million USD | -25.28% |
| 2020 FY | -13.76 Million USD | -1.21% |
| 2019 Q2 | -3.35 Million USD | -6.51% |
| 2019 FY | -13.59 Million USD | -28.4% |
| 2019 Q3 | -3.5 Million USD | -4.38% |
| 2019 Q1 | -3.15 Million USD | -1.48% |
| 2019 Q4 | -3.82 Million USD | -9.31% |
| 2018 Q3 | -2.7 Million USD | -1.81% |
| 2018 FY | -10.58 Million USD | -8.37% |
| 2018 Q4 | -3.1 Million USD | -14.84% |
| 2018 Q2 | -2.65 Million USD | -224.82% |
| 2018 Q1 | 2.12 Million USD | 211.83% |
| 2017 Q2 | -2.83 Million USD | -6.55% |
| 2017 Q3 | -7.86 Million USD | -178.06% |
| 2017 Q4 | -1.9 Million USD | 75.83% |
| 2017 FY | -9.77 Million USD | -10.71% |
| 2017 Q1 | -2.65 Million USD | -10.57% |
| 2016 Q3 | -1.69 Million USD | 14.92% |
| 2016 FY | -8.82 Million USD | 28.19% |
| 2016 Q1 | -2.74 Million USD | 7.71% |
| 2016 Q2 | -1.99 Million USD | 27.43% |
| 2016 Q4 | -2.4 Million USD | -41.88% |
| 2015 Q2 | -3.93 Million USD | 4.33% |
| 2015 Q1 | -4.11 Million USD | -164.37% |
| 2015 Q4 | -2.97 Million USD | -6089.58% |
| 2015 Q3 | -48 Thousand USD | 98.78% |
| 2015 FY | -12.29 Million USD | -201.52% |
| 2014 Q3 | -292 Thousand USD | 74.43% |
| 2014 Q1 | -1.08 Million USD | 33.25% |
| 2014 Q2 | -1.14 Million USD | -5.06% |
| 2014 Q4 | -1.55 Million USD | -432.53% |
| 2014 FY | -4.07 Million USD | -2.03% |
| 2013 Q2 | -1.07 Million USD | -3.91% |
| 2013 Q4 | -1.62 Million USD | 0.0% |
| 2013 FY | -3.99 Million USD | -7.36% |
| 2013 Q1 | -1.03 Million USD | 0.0% |
| 2013 Q3 | -1.62 Million USD | -51.49% |
| 2012 FY | -3.72 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 80.145% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -76.615% |
| Aspira Women's Health Inc. | -16.69 Million USD | -5.261% |
| Biodesix, Inc. | -52.14 Million USD | 66.31% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -568.228% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -121.343% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -121.343% |
| Bionano Genomics, Inc. | -232.49 Million USD | 92.444% |
| CareDx, Inc | -190.28 Million USD | 90.767% |
| Castle Biosciences, Inc. | -57.46 Million USD | 69.429% |
| DarioHealth Corp. | -59.42 Million USD | 70.438% |
| Exact Sciences Corporation | -204.14 Million USD | 91.395% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 89.532% |
| Guardant Health, Inc. | -479.44 Million USD | 96.336% |
| ICON Public Limited Company | 612.33 Million USD | 102.869% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 102.079% |
| Illumina, Inc. | -1.16 Billion USD | 98.487% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -72.969% |
| iSpecimen Inc. | -11.09 Million USD | -58.278% |
| Standard BioTools Inc. | -74.65 Million USD | 76.468% |
| MDxHealth SA | -43.1 Million USD | 59.239% |
| 23andMe Holding Co. | -666.7 Million USD | 97.365% |
| Medpace Holdings, Inc. | 282.81 Million USD | 106.212% |
| Myriad Genetics, Inc. | -112 Million USD | 84.314% |
| Mainz Biomed B.V. | -26.29 Million USD | 33.191% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -74.628% |
| NeoGenomics, Inc. | -87.96 Million USD | 80.029% |
| Neogen Corporation | -9.42 Million USD | -86.477% |
| Inotiv, Inc. | -105.14 Million USD | 83.291% |
| Natera, Inc. | -434.8 Million USD | 95.96% |
| OpGen, Inc. | -32.66 Million USD | 46.223% |
| OPKO Health, Inc. | -188.86 Million USD | 90.698% |
| Psychemedics Corporation | -4.15 Million USD | -322.918% |
| Prenetics Global Limited | -62.72 Million USD | 71.992% |
| Prenetics Global Limited | -62.72 Million USD | 71.992% |
| Precipio, Inc. | -5.85 Million USD | -200.154% |
| Personalis, Inc. | -108.29 Million USD | 83.778% |
| RadNet, Inc. | 3.04 Million USD | 677.135% |
| Sera Prognostics, Inc. | -36.24 Million USD | 51.526% |
| Sotera Health Company | 51.37 Million USD | 134.195% |
| Neuronetics, Inc. | -30.18 Million USD | 41.807% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -1034.884% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -1034.884% |
| Trinity Biotech plc | -24.01 Million USD | 26.855% |
| T2 Biosystems, Inc. | -50.07 Million USD | 64.918% |
| Twist Bioscience Corporation | -208.72 Million USD | 91.583% |
| Exagen Inc. | -23.68 Million USD | 25.839% |